Effects of Gastric Bypass on Type 2 Diabetes in Patients with BMI 30 to 35

Scopinaro, Nicola; Adami, Giovanni; Papadia, Francesco; Camerini, Giovanni; Carlini, Flavia; Briatore, L.; Andraghetti, Gabriella; Catalano, Mariafrancesca; Cordera, Renzo

doi:10.1007/s11695-014-1206-1

Cited by 27 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of obesity in patients with diabetes and cardiovascular diseases has been proven to be a major risk factor of premature death. This risk is lower among individuals with normal weight and optimal glycemic control [5][6][7][8][9][10].…”

Section: Background and Aims: Recent Studies Have Brought Evidence Onmentioning

confidence: 99%

Body Mass Index and Glycaemic Control in Patients with Diabetes Mellitus: A Case-Control Study

Mut-Vitcu

Hudrea

Moşteoru

et al. 2017

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

View full text Add to dashboard Cite

show abstract

Section: Background and Aims: Recent Studies Have Brought Evidence Onmentioning

confidence: 99%

Body Mass Index and Glycaemic Control in Patients with Diabetes Mellitus: A Case-Control Study

Mut-Vitcu

Hudrea

Moşteoru

et al. 2017

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

View full text Add to dashboard Cite

show abstract

“…Surgical treatment was standardized in all studies. 39,43,44 The target HbA1c level for remission of T2DM ranged from 6.0% to 7.0%. Medical treatment was not standardized in 5 OCSs.…”

Section: Study Quality and Critical Appraisalmentioning

confidence: 99%

“…With regard to comorbidities, arterial hypertension was defined in only 1 study44 and dyslipidemia was not defined in any of the studies. The effect of surgery compared to medical treatment on the glycemic control rate is shown as the OR with its 95% CI.…”

mentioning

confidence: 99%

Surgical Versus Medical Treatment of Type 2 Diabetes Mellitus in Nonseverely Obese Patients

Müller‐Stich¹,

Senft²,

Warschkow³

et al. 2015

Annals of Surgery

129

View full text Add to dashboard Cite

show abstract

“…The antidiabetic mechanisms are weight independent, which has prompted considerations of applying these surgeries to T2D patients with only mild (stage 1) obesity (BMI 30–35 kg m −2 ) . Initial studies where RYGB surgery was applied to diabetic patients with stage 1 obesity indeed revealed significant but inconsistent remission rates between 25% and 88% .…”

Section: Introductionmentioning

confidence: 99%

Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

et al. 2018

View full text Add to dashboard Cite

Obesity and its comorbidities, such as type 2 diabetes, are pressing worldwide health concerns. Available anti-obesity treatments include weight loss pharmacotherapies and bariatric surgery. Whilst surgical interventions typically result in significant and sustained weight loss, available pharmacotherapies are far less effective, typically decreasing body weight by no more than 5-10%. An emerging class of multi-agonist drugs may eventually bridge this gap. This new class of specially tailored drugs hybridizes the amino acid sequences of key metabolic hormones into one single entity with enhanced potency and sustained action. Successful examples of this strategy include multi-agonist drugs targeting the receptors for glucagon-like peptide-1 (GLP-1), glucagon and the glucose-dependent insulinotropic polypeptide (GIP). Due to the simultaneous activity at several metabolically relevant receptors, these multi-agonists offer improved body weight loss and glucose tolerance relative to their constituent monotherapies. Further advancing this concept, chimeras were generated that covalently link nuclear acting hormones such as oestrogen, thyroid hormone (T ) or dexamethasone to peptide hormones such as GLP-1 or glucagon. The benefit of this strategy is to restrict the nuclear hormone action exclusively to cells expressing the peptide hormone receptor, thereby maximizing combinatorial metabolic efficacy of both drug constituents in the target cells whilst preventing the nuclear hormone cargo from entering and acting on cells devoid of the peptide hormone receptor, in which the nuclear hormone might have unwanted effects. Many of these multi-agonists are in preclinical and clinical development and may represent new and effective tools in the fight against obesity and its comorbidities.

show abstract

Effects of Gastric Bypass on Type 2 Diabetes in Patients with BMI 30 to 35

Abstract: Glycemic control obtained by RYGB in this study was less good than that reported by others, apparently due to different patient selection criteria. Our results do not support RYGB weight loss-independent effect on beta-cell function in the T2DM patients with BMI 30-35 kg/m(2).

Cited by 27 publications

References 30 publications

Body Mass Index and Glycaemic Control in Patients with Diabetes Mellitus: A Case-Control Study

Body Mass Index and Glycaemic Control in Patients with Diabetes Mellitus: A Case-Control Study

Surgical Versus Medical Treatment of Type 2 Diabetes Mellitus in Nonseverely Obese Patients

Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

Contact Info

Product

Resources

About